The introduction of new inactivated vaccines upon completion of clinical trials is expected to drive the growth of the
inactivated vaccines market over the forecast period. In the first Phase III study, an estimated 64% of shingles are found in immunocompromised subjects. Clinical studies also showed that V212 reduced the incidence of shingles pains by approximately 69.5%. In addition, V212 showed an 83.7% reduction in the incidence of postherpetic neuralgia. The increasing prevalence of various viral and bacterial diseases around the world has increased the demand for inactivated vaccines, which in turn will fuel market growth. For example, according to the World Health Organization (WHO) report from 2018, annual epidemics from influenza are estimated at around 3 to 5 million cases of serious illness and around 290,000 to 650,000 deaths. The 2018 WHO report also showed that there are around 21 million cases and 222,000 typhoid-related deaths annually worldwide.
Depending on the region, the global inactivated vaccine market is divided into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. North America is taking a dominant position in the global inactivated vaccine market due to the presence of key players in the market in this region, particularly in the United States, accelerating sales growth from the inactivated vaccine market in this region. In 2016, for example, the US department of Health transferred about $81 million from other projects to continue vaccine development to fight the Zika virus. Market growth is expected for the Asia-Pacific region, followed by, for example, in 2013, Bharat Biotech launched the JENVAC vaccine, which offers long-term protection and immunogenicity against Japanese encephalitis. Which can be administered during disease epidemics as it is an inactivated vaccine and is highly purified.
